{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-262193","form_type":"8-K","ticker":"KYMR","cik":"0001815442","company_name":"Kymera Therapeutics, Inc.","filed_at":"2022-10-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.272384+00:00","generated_at":"2026-06-23T03:53:20.205454+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Kymera completes KT-474 Phase 1 Part C dosing; webcast Dec 14 for data","bullets":["Completed dosing in Part C of KT-474 Phase 1 trial for hidradenitis suppurativa and atopic dermatitis.","Will hold investor webcast on December 14, 2022 to present clinical data from KT-474 and oncology pipeline.","KT-333 (STAT3 degrader) and KT-413 (IRAKIMiD) continuing Phase 1 dose escalation.","KT-253 (MDM2 degrader) has completed IND enabling studies; expects to file IND by year-end 2022.","Collaboration with Sanofi for IRAK4 degrader development outside oncology/immune-oncology."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-262193","json":"https://secwatch.observer/filing/0001193125-22-262193.json","markdown":"https://secwatch.observer/filing/0001193125-22-262193.md","text":"https://secwatch.observer/filing/0001193125-22-262193.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1815442/000119312522262193/0001193125-22-262193-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1815442/000119312522262193/d396584d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T03:53:20.205454+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}